Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hyaluronidase/pertuzumab/trastuzumab - Roche

Next Previous
Drug Profile

Hyaluronidase/pertuzumab/trastuzumab - Roche

Alternative Names: Herceptin/perjeta; Perjeta/herceptin; Pertuzumab FDC SC; Pertuzumab/trastuzumab; Pertuzumab/trastuzumab/hyaluronidase-zzxf; Pertuzumab/trastuzumab/vorhyaluronidase alfa; PH FDC SC; Phesgo; Phesgo OBI; RG-6264; Trastuzumab/pertuzumab

Latest Information Update: 04 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Medica Scientia Innovation Research; Merck & Co; Roche; Seagen
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors; Hyaluronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer; HER2 positive breast cancer
  • Phase II Solid tumours

Most Recent Events

  • 01 Apr 2026 Registered for HER2-positive-breast-cancer in China (SC)
  • 19 Jan 2026 Hoffmann-La Roche completes a phase-III clinical trials in Her2 positive Breast cancer (Combination therapy, Late-stage disease) in China (SC) (NCT04024462)
  • 07 Nov 2025 Roche completes the Phase-III ProHer clinical trials in HER2-positive-breast-cancer (Neoadjuvant therapy, Combination therapy) in Argentina, Bosnia and Herzegovina, Bulgaria, Brazil, Chile, Costa Rica, Croatia, India, Kenya, South Korea, Peru, South Africa, Singapore, Turkey, Canada, Mexico and Spain (SC) (NCT05415215)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top